Shopping Cart
- Remove All
- Your shopping cart is currently empty
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $263 | In Stock | |
5 mg | $588 | In Stock | |
10 mg | $947 | In Stock | |
25 mg | $1,380 | In Stock | |
50 mg | $1,890 | In Stock | |
100 mg | $2,550 | In Stock |
Description | Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin). |
In vitro | Glembatumumab vedotin (CR011-vcMMAE) exhibits minimal growth inhibition at a concentration of 0.16 μg/mL in UACC62 melanoma cells without prior MEK inhibitor pretreatment for 72 hours. In contrast, the same dose of CR011-vcMMAE shows stronger growth inhibition in UACC62 cells pre-treated with a MEK inhibitor[1]. |
In vivo | Glembatumumab vedotin, administered via intravenous injection at a dose of 2.5 mg/kg three times within 7 days, inhibits tumor growth and demonstrates good tolerance in CB17SC scid?/? female xenograft mice[2]. |
Molecular Weight | 145.56 kDa |
Cas No. | 1020264-78-1 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.